ach FY pretax beats, ups div 10%, positive outlook, revs inline, good start to year (trading +5.6%) Grifols competitor Baxter gets FDA approval for Gammagard (MMN treatment) (GRF SM trading -0.41%) Absa Group profit warning mainly due to higher provisions, likely from legacy mortgages (trading -8.1%) G